Claire Bewshea
University of Exeter(GB)Royal Devon and Exeter Hospital(GB)
Publications by Year
Research Areas
Inflammatory Bowel Disease, SARS-CoV-2 and COVID-19 Research, Microscopic Colitis, COVID-19 Clinical Research Studies, Immunodeficiency and Autoimmune Disorders
Most-Cited Works
- → Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study(2019)659 cited
- → HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease(2019)400 cited
- → Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD(2021)276 cited
- → HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants(2014)188 cited
- → Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease(2019)168 cited
- → Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.(2021)163 cited
- → COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study(2022)147 cited
- → Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease(2015)112 cited
- → Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study(2024)111 cited
- → Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab(2022)81 cited